Celerity is excited to offer deeper, more adaptable, and more accessible sequencing power to our collaboration partners than ever before.
Announcing TruSight™ Oncology 500 for tumor mutational burden assessment
The VENTANA pan-TRK (EPR17341) Assay is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types
The assay is expected to provide improved data on the prevalence of TRK proteins in tumor tissue studies
The significance of TRK fusion proteins is currently being investigated in various cancer indications
Roche launches first IVD pan-TRK immunohistochemistry assay
With over 70 pathologist and nearly 130 laboratory assistants communication and effective operation within Celerity's Network of Laboratories is critical. Former laboratory directors and educators Paul Bachner and David Wilkinson share the lessons they’ve learned over nearly a century of combined experience.